NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy
- PMID: 32462261
- DOI: 10.1007/s10549-020-05692-5
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy
Abstract
Background: Chemotherapy-induced amenorrhea (CIA) is one of the critical side effects from the chemotherapy in premenopausal patients with breast cancer. The goals of our study are the following: (1) to investigate the factors affecting the incidence of CIA; and (2) to evaluate the prognostic role of CIA in premenopausal patients with breast cancer.
Methods: We conducted a post hoc retrospective substudy to examine the incidence of the CIA and the relationship between CIA and prognosis in NSAS-BC02 that compared taxane alone to Doxorubicin(A) Cyclophosphamide(C) followed by taxane in postoperative patients with node-positive breast cancer RESULTS: Of 395 premenopausal women, 287 (72.7%) had CIA due to protocol treatment. Regarding type of protocol regimen, proportion of CIA was 76.9% in AC Paclitaxel(P), 75.2% in AC Docetaxel(D), 62.8% in PTX, and 75.2% in DTX. Predictive factors of CIA were age increase by 5 years (OR 1.50), ER positivity (OR 2.08), and HER2 3 + ( OR 0.40) according to logistic regression analysis. According to the log rank test and the Cox proportional hazards model, CIA group had significantly better disease-free survival than non-CIA group (P < .0001). However, according to time-dependent Cox model that was used to reduce guarantee-time bias, CIA was not a statistically significant prognostic factor in both ER-positive and ER-negative patients.
Conclusion: Treatment with taxane alone caused high frequency of CIA in premenopausal women with breast cancer. CIA did not turn out to be an independent prognostic factor, taking guarantee-time bias into consideration. Further clinical studies are needed to validate these findings.
Keywords: Breast cancer; Chemotherapy-induced amenorrhea; Guarantee-time bias; Premenopause; Taxane.
Similar articles
-
Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.Menopause. 2011 Feb;18(2):208-12. doi: 10.1097/gme.0b013e3181f3e6e7. Menopause. 2011. PMID: 21037487
-
The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.Am J Clin Oncol. 2007 Apr;30(2):126-32. doi: 10.1097/01.coc.0000251398.57630.4f. Am J Clin Oncol. 2007. PMID: 17414460
-
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.Breast Cancer Res Treat. 2009 May;115(2):335-42. doi: 10.1007/s10549-008-0071-9. Epub 2008 May 28. Breast Cancer Res Treat. 2009. PMID: 18506620 Clinical Trial.
-
Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature.Menopause. 2015 Oct;22(10):1091-7. doi: 10.1097/GME.0000000000000440. Menopause. 2015. PMID: 25783467 Free PMC article. Review.
-
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.JAMA Oncol. 2015 Dec;1(9):1311-8. doi: 10.1001/jamaoncol.2015.3062. JAMA Oncol. 2015. PMID: 26402167 Free PMC article. Review.
Cited by
-
Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review.Curr Oncol Rep. 2024 Nov 5. doi: 10.1007/s11912-024-01615-5. Online ahead of print. Curr Oncol Rep. 2024. PMID: 39499484 Review.
-
Oncofertility as an Essential Part of Comprehensive Cancer Treatment in Patients of Reproductive Age, Adolescents and Children.Cancers (Basel). 2024 May 13;16(10):1858. doi: 10.3390/cancers16101858. Cancers (Basel). 2024. PMID: 38791937 Free PMC article. Review.
-
Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel-related ovarian damage in mice.Sci Rep. 2023 Dec 20;13(1):22782. doi: 10.1038/s41598-023-49578-0. Sci Rep. 2023. PMID: 38129495 Free PMC article.
-
Investigation of the female infertility risk associated with anti-cancer therapy.Clin Transl Oncol. 2023 Jul;25(7):1893-1905. doi: 10.1007/s12094-023-03087-8. Epub 2023 Jan 23. Clin Transl Oncol. 2023. PMID: 36689055 Review.
-
The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence.Front Endocrinol (Lausanne). 2022 Nov 24;13:1025018. doi: 10.3389/fendo.2022.1025018. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36531475 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous